Liposomal amphotericin B and amphotericin B-deoxycholate show different immunoregulatory effects on human peripheral blood mononuclear cells

Journal of Infectious Diseases

Volumn 181, Issue 6, 2000, Pages 2003-2010

  Reyes, Eduardo ^a   Cardona, Jorge ^a   Prieto, Alfredo ^a   Bernstein, Erica D ^a   Rodríguez Zapata, Manuel ^a,b   Pontes, Maria José ^c   Alvarez Mon, Melchor ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c Nextar Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBISOMC; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; FUNGIZONA;

ADULT; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; DRUG EFFECT; HUMAN; IMMUNOREGULATION; MONONUCLEAR CELL; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; APOPTOSIS; CELL SURVIVAL; DEOXYCHOLIC ACID; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOSOMES; LYMPHOCYTE ACTIVATION; MACROPHAGES;

EID: 0034100222     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315517     Document Type: Article

References (62)

1. 1. O'Neil MG, Lapointe M. Administration of amphotericin B in lipid emulsion. Crit Care Med 1997; 25:892-3.
2. 2. Leenders AC, de Marie S, ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. J Antimicrob Chemother 1996; 38: 215-25.
3. 3. de Marie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia 1996; 10(Suppl 2):S93-S96.
4. 4. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22(Suppl 2):S133-44.
5. 5. Legrand P, Vertut-Doi A, Bolard J. Liposomal amphotericin B bases of therapeutic index increase. Biomater Artif Cells Immobilization Biotechnol 1993; 21:407-13.
6. 6. Heinemann V, Bosse D, Jehn U, et al. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob Agents Chemother 1997; 41:1275-80.
7. 7. Abu-Salah KM. Amphotericin B: an update. Br J Biomed Sci 1996; 53: 122-33.
8. 8. McCusker ME, Garifallou M, Bogen SA. Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation. J Immunol 1997; 158: 4984-91.
9. 9. Kalinski P, Hilkens CM, Wierenga EA, et al. Functional maturation of human naive T helper cells in the absence of accessory cells. Generation of IL-4-producing T helper cells does not require exogenous IL-4. J Immunol 1995; 154:3753-60.
10. 10. Vonk AG, Netea MG, Denecker NE, Verschueren IC, van der MJ, Kullberg BJ. Modulation of the pro-and anti-inflammatory cytokine balance by amphotericin B. J Antimicrob Chemother 1998; 42:469-74.
11. 11. Trinchieri G, Kubin M, Bellone G, Cassatella MA. Cytokine cross-talk between phagocytic cells and lymphocytes: relevance for differentiation/activation of phagocytic cells and regulation of adaptive immunity. J Cell Biochem 1993; 53:301-8.
12. + T cell responses in human leprosy. J Immunol 1998; 161:2407-13.
13. 13. Woeltje KF, Mathew A, Rothstein M, Seiler S, Fraser VJ. Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis 1998; 31: 848-52.
14. 14. Barwicz J, Tancrede P. The effect of aggregation state of amphotericin-B on its interactions with cholesterol- or ergosterol-containing phosphatidyl-choline monolayers. Chem Phys Lipids 1997; 85:145-55.
15. 15. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 1998; 38:583-92.
16. 16. Mehta RT, Mehta K, Lopez-Berestein G, Juliano RL. Effect of liposomal amphotericin B on murine macrophages and lymphocytes. Infect Immun 1985; 47:429-33.
17. 17. Okutomi T, Ubukata T, Yamaoka K, Abe S, Yamaguchi H. Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice. Br J Cancer 1997; 75:1613-6.
18. 18. Rogers PD, Jenkins JK, Chapman SW, Ndebele K, Chapman BA, Cleary JD. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis 1998; 178:1726-33.
19. + T helper type 1 cell responses to Candida albicans. J Exp Med 1998; 187:307-17.
20. 20. Boyum A. Isolation of mononuclear cells and granulocytes from human blood: isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest 1968; 97(Suppl):77-89.
21. 21. Schmid I, Krall WJ, Uittenbogaart CH, Braun J, Giorgi JV. Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry 1992; 13: 204-8.
22. 22. Prieto A, Reyes E, Diaz D, et al. A new method for the simultaneous analysis of growth and death of immunophenotypically defined cells in culture. Cytometry 2000; 39:56-66.
23. 23. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
24. 24. Gulati M, Bajad S, Singh S, Ferdous AJ, Singh M. Development of liposomal amphotericin B formulation. J Microencapsul 1998; 15:137-51.
25. 25. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103:205-12.
26. 26. Coukell AJ, Brogden RN. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 1998; 55:585-612.
27. 27. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764-71.
28. 28. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98:711-8.
29. 29. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995; 155:1093-8.
30. 30. Chopra R, Blair S, Strang J, Cervi P, Patterson KG, Goldstone AH. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother 1991; 28(Suppl B): 93-104.
31. 31. Lopez-Berestein G, Bodey GP, Frankel LS, Mehta K. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol 1987; 5:310-7.
32. 32. Shirkhoda A, Lopez-Berestein G, Holbert JM, Luna MA. Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology 1986; 159:349-53.
33. 33. Patel R. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc 1998; 73:1205-25.
34. 34. Mehta RT, Poddar S, Kalidas M, Gomez-Flores R, Dulski K. Role of macrophages in the candidacidal activity of liposomal amphotericin B. J Infect Dis 1997; 175:214-7.
35. 35. Jahn B, Rampp A, Dick C, Jahn A, Palmer M, Bhakdi S. Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level. Antimicrob Agents Chemother 1998; 42:2569-75.
36. 36. Marzzullo L, Souza LC, Campa A. Effect of amphotericin B associated with a lipid emulsion on the oxidative burst of human polymorphonuclear leukocytes. Gen Pharmacol 1997; 28:203-7.
37. 37. Nosanchuk JD, Cleare W, Franzot SP, Casadevall A. Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations. Antimicrob Agents Chemother 1999; 43:233-9.
38. 38. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998; 26:1266-9.
39. 39. Cenci E, Mencacci A, Del Sero G, Bistoni F, Romani L. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. J Infect Dis 1997; 176: 217-26.
40. 40. Mozaffarian N, Berman JW, Casadevall A. Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob Agents Chemother 1997; 41:1825-9.
41. 41. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet 1992; 23:279-91.
42. 42. Mehta RT, McQueen TJ, Keyhani A, Lopez-Berestein G. Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy 1994; 40:256-64.
43. 43. Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, Walsh TJ. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 1994; 38:713-8.
44. 44. Juliano RL, Grant CW, Barber KR, Kalp MA. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 1987; 31:1-11.
45. 45. Cohen BE. Concentration- and time-dependence of amphotericin-B induced permeability changes across ergosterol-containing liposomes. Biochim Biophys Acta 1986; 857:117-22.
46. 46. Joly V, Saint-Pierre-Chazalet M, Saint-Julien L, Bolard J, Carbon C, Yeni P. Inhibiting cholesterol synthesis reduces the binding and toxicity of amphotericin B against rabbit renal tubular cells in primary culture. J Infect Dis 1992; 165:337-43.
47. 47. Barwicz J, Dumont I, Quellet C, Gruda I. Amphotericin B toxicity as related to the formation of oxidatively modified low-density lipoproteins. Biospectroscopy 1998; 4:135-14.
48. 48. Cohen BE. A sequential mechanism for the formation of aqueous channels by amphotericin B in liposomes. The effect of sterols and phospholipid composition. Biochim Biophys Acta 1992; 1108:49-58.
49. 49. Ramos H, Valdivieso E, Gamargo M, Dagger F, Cohen BE. Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. J Membr Biol 1996; 152:65-75.
50. 50. Fujii G, Chang JE, Coley T, Steere B. The formation of amphotericin B ion channels in lipid bilayers. Biochemistry 1997; 36:4959-68.
51. 51. Lee JM. Inhibition of p53-dependent apoptosis by the KIT tyrosine kinase: regulation of mitochondrial permeability transition and reactive oxygen species generation. Oncogene 1998; 17:1653-62.
52. 52. Lemasters JJ, Nieminen AL, Qian T, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998; 1366:177-96.
53. 53. Lemasters JJ. V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Am J Physiol 1999; 276(1 Pt I):G1-G6.
54. 54. Sheng-Tanner X, Bump EA, Hedley DW. An oxidative stress-mediated death pathway in irradiated human leukemia cells mapped using multilaser flow cytometry. Radiat Res 1998; 150:636-47.
55. 55. Legrand P, Vertut-Doi A, Bolard J. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother 1996; 37:519-33.
56. 56. Legrand P, Cheron M, Leroy L, Bolard J. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J Drug Target 1997; 4:311-9.
57. 57. Wrobel I, Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim Biophys Acta 1995; 1235:296-304.
58. 58. Osaka K, Ritov VB, Bernardo JF, Branch RA, Kagan VE. Amphotericin B protects cis-parinaric acid against peroxyl radical-induced oxidation: amphotericin B as an antioxidant. Antimicrob Agents Chemother 1997; 41; 743-7.
59. 59. Osaka K, Tyurina YY, Dubej RK, et al. Amphotericin B as an intracellular antioxidant: protection against 2,2′-azobis(2,4-dimethylvaleronitrile)-induced peroxidation of membrane phospholipids in rat aortic smooth muscle cells. Biochem Pharmacol 1997; 54:937-45.
60. 60. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995; 38:459-65.
61. 61. Rapp RP, Gubbins PO, Evans ME. Amphotericin B lipid complex. Ann Pharmacother 1997; 31:1174-86.
62. 62. Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 1998; 16:365-96.